home / stock / aim / aim news

AIM News and Press, AIM ImmunoTech Inc. From 05/16/24

Stock Information
Company Name: AIM ImmunoTech Inc.
Stock Symbol: AIM
Market: NYSE
Website: aimimmuno.com
Menu
AIM AIM Quote AIM Short AIM News AIM Articles AIM Message Board
Get AIM Alerts

News, Short Squeeze, Breakout and More Instantly...
AIM - AIM ImmunoTech GAAP EPS of -$0.12

2024-05-16 07:33:17 ET More on AIM ImmunoTech AIM ImmunoTech Inc. (AIM) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on AIM ImmunoTech Historical earnings data for AIM ImmunoTech Financial information for AIM ImmunoTech Read ...
AIM - AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update

Continued execution across Ampligen ® clinical development programs and growing body of positive data in multiple high-value indications Company to host conference call and webcast today, May 16, at 8:30 AM ET OCALA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech...

AIM - Notable earnings before Thursday's open

2024-05-15 11:47:59 ET Major earnings expected before the bell on Thursday include: Baidu ( BIDU ) Deere & Co. ( DE ) JD.com( JD ) Under Armour ( UAA ) Walmart ( WMT ) Other earnings slated for release before Thursday's open include: ...

AIM - AIM ImmunoTech Q1 2024 Earnings Preview

2024-05-15 11:26:43 ET More on AIM ImmunoTech AIM ImmunoTech Inc. (AIM) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on AIM ImmunoTech Historical earnings data for AIM ImmunoTech Financial information for AIM ImmunoTech Read ...
AIM - AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q1 2024 operational and financial res...

AIM - AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen ® (rintatolimod), AIM’s...

AIM - AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

OCALA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has taken an essential step forward in testing the combination of AIM’s Ampligen® (rintatolimod) and AstraZ...
AIM - AIM ImmunoTech files to sell 9.98M shares of common stock for holders

2024-04-19 17:12:59 ET More on AIM ImmunoTech AIM stock dips amid mixed results for post-COVID fatigue therapy Seeking Alpha’s Quant Rating on AIM ImmunoTech Historical earnings data for AIM ImmunoTech Financial information for AIM ImmunoTech ...

AIM - AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs

OCALA, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop Ampligen (rintatolimod) as a potential treatment for Myalgic encephalomyelit...

AIM - AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

OCALA, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab) in the treatment of recurrent ovarian cancer may have a ...
Previous 10 Next 10